InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,247.94
(
0.25%
)
Post# of 252301
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 06/02/2006 2:45:03 PM

Friday, June 02, 2006 2:45:03 PM

Post# of 252301
GTCB (from SI):

>>
From: DewDiligence_on_SI
6/2/2006 2:30:43 PM
To: Sam Citron who wrote (2517) of 2518

> How do you see this news impacting chance for US approval?<

The U.S. ATryn program figures to be an easier sell to the regulators for two reasons:

1. The U.S. phase-3 trial is larger and contains a control arm.

2. The unmet medical need in the U.S. is greater because (unlike Europe) plasma-derived antithrombin is rarely available in the U.S.

I think the probability of FDA approval for ATryn in 2008 is about 85%. Regards, Dew
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up